Mather Group’s West Pharmaceutical WST Stock Holding History

Mather Group’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$344K	Buy	928 +43	+5%	+$15.2K	﹤0.01%	647
2026 Q2	$318K	Sell	885 -22	-2%	-$6.73K	﹤0.01%	656
2026 Q1	$227K	Buy	+907	New	+$226K	﹤0.01%	700
2025 Q4	–	Sell	-686	Closed	-$180K	–	1658
2025 Q3	$180K	Buy	+686	New	+$167K	﹤0.01%	652
2025 Q2	–	Sell	-884	Closed	-$198K	–	1731
2025 Q1	$198K	Sell	884 -225	-20%	-$62K	﹤0.01%	591
2024 Q4	$363K	Sell	1,109 -357	-24%	-$112K	﹤0.01%	425
2024 Q3	$440K	Buy	1,466 +143	+11%	+$43.8K	0.01%	394
2024 Q2	$524K	Buy	1,323 +142	+12%	+$50.2K	0.01%	406
2024 Q1	$416K	Hold	1,181	–	–	0.01%	377
2023 Q4	$416K	Sell	1,181 -54	-4%	-$19.1K	0.01%	388
2023 Q3	$463K	Buy	1,235 +46	+4%	+$17.8K	0.01%	339
2023 Q2	$455K	Buy	1,189 +297	+33%	+$106K	0.01%	366
2023 Q1	$309K	Buy	+892	New	+$261K	0.01%	389
2022 Q4	–	Sell	-1,011	Closed	-$249K	–	513
2022 Q3	$249K	Sell	1,011 -12	-1%	-$3.66K	0.01%	410
2022 Q2	$309K	Buy	+1,023	New	+$333K	0.01%	303

Other funds holding WST

Border to Coast Pensions Partnership Leeds, United Kingdom $7.27B AUM 24.98% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

AMI Asset Management Los Angeles, California $1.74B AUM 24.77% 1-Year Est. Return

Seilern Investment Management London, United Kingdom $771M AUM 2.59% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

North Growth Management Vancouver, British Columbia, Canada $743M AUM 74.29% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

MCG

McCollum Christoferson Group Amherst, New York $343M AUM 13.42% 1-Year Est. Return

Mather Group's WST Position: Q3 2026 in Review

Mather Group increased its West Pharmaceutical (WST) stake by 4.9% in Q3 2026, buying an estimated $15.2K and bringing the position to 928 shares worth $344K. The position accounts for ﹤0.01% of the portfolio, ranked #647.

Mather Group first reported a position in WST in Q2 2022 and has held it in 15 quarters since. The position peaked at $524K in Q2 2024. 142 funds tracked by Wall St. Rank hold WST as of Q3 2026.

Mather Group held 928 shares of West Pharmaceutical worth $344K as of Q3 2026.
Mather Group bought 43 West Pharmaceutical shares in Q3 2026, an estimated $15.2K.
West Pharmaceutical made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #647 holding.
Mather Group first reported a position in West Pharmaceutical in Q2 2022 and has held it in 15 quarters since.
Mather Group's West Pharmaceutical position peaked at $524K in Q2 2024.
142 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.